Citi analyst Daniel Grosslight upgraded Hims & Hers to Neutral from Sell with a price target of $24, up from $13.25.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Needham Upgrades Hims & Hers Stock (HIMS) after Novo Nordisk Deal Resets Weight Loss Outlook
- Morning News Wrap-Up 3/9/26: Monday’s Biggest Stock Market Stories!
- Moderately bullish activity in Hims and Hers Health with shares up 39.33%
- Hims & Hers rises 38.4%
- Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ